News: Novartis AG (NOVN.VX)
73.65CHF
11:31am EDT
CHF1.25 (+1.73%)
CHF72.40
CHF72.30
CHF73.75
CHF72.20
4,954,414
5,019,366
CHF73.75
CHF48.85
Fri, May 10 2013
Novartis, BT push European shares to fresh 5-yr peak
LONDON, May 10 - European shares scaled fresh five-year highs on Friday, led by healthcare group Novartis and telecoms firm BT on positive corporate news, and traders said key indexes had scope for more gains.
U.S. approves Novartis drug Ilaris to treat childhood arthritis
ZURICH, May 10 - Novartis said on Friday the U.S. Food and Drug Administration (FDA) had approved its drug Ilaris to treat a serious form of childhood arthritis.
U.S. sues Novartis over kickbacks
NEW YORK - The U.S. government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs.
U.S. sues Novartis over kickbacks, second case this week
NEW YORK - The U.S. government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs.
UPDATE 2-U.S. sues Novartis over kickbacks, 2nd case this week
NEW YORK, April 26 - The U.S. government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs.
U.S. files 2nd lawsuit accusing Novartis of kickbacks
April 26 - The U.S. government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multi-million dollar kickbacks to doctors in exchange for prescribing its drugs.
BRIEF-U.S. joins whistleblower lawsuit against Novartis over alleged kickbacks
April 26 - Novartis AG : * U.S. says joins whistleblower lawsuit against Novartis AG over
UPDATE 2-Novartis names new finance chief to boost productivity
* Reports earnings per share of $1.32 vs estimates for $1.30
BRIEF-Novartis to cut 300 jobs at consumer health unit
ZURICH, April 24 - Novartis AG : * Says will cut some 300 positions at consumer health unit, as downsizes
Novartis names Harry Kirsch new CFO
ZURICH, April 24 - Swiss drugmaker Novartis named Harry Kirsch as new Chief Financial Officer to help improve productivity as the Basel-based drugmaker looks to grow beyond a wave of patent expiries.
Press Releases
- New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations
- Largest-ever global survey of 1,273 women in 12 countries reveals women with advanced breast cancer feel left out of the breast cancer movement
- Novartis drug Afinitor(R) significantly extended time without disease progression in women with HER2 positive advanced breast cancer
- Novartis wins GBCHealth Business Action on Health Award for social ventures initiative
- Novartis drug Ilaris(R) approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
- Real-world data at ARVO highlight transformational outcomes seen with Lucentis(R), including lower injection frequency than in original clinical trials
- Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
- Malaria No More Announces Innovative Partners For Its 'Power Of One' Malaria Campaign
- Novartis signs on to support Malaria No More's Power of One campaign to stride towards a future without malaria
- Novartis discloses compensation for new Chairman and Chairman ad-interim
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
